- The company is testing 5 and 25 microgram doses in
an early stage study; results are expected in July
- Novavax’s insect-cell technology and the 5 microgram dose can be scaled up easily, R&D president
Gregory Glennsaid, speaking at the second ISV Covid-19 Vaccines Virtual Congress
- NVAX has $1.6 billion in funding from the U.S. government as well as backing
- Company is on track for for 100m doses to U.S. by...
July 21, 2020, 3:27 PM